In vivo local co-delivery of recombinant human bone morphogenetic protein-7 and pamidronate via poly-D, L-lactic acid

European Cells and Materials

Volumn 20, Issue , 2010, Pages 431-442

  Yu, Nicole Y C ^a,b   Schindeler, Aaron ^a,b   Peacock, Lauren ^a   Mikulec, Kathy ^a   Baldock, Paul A ^c   Ruys, Andrew J ^b   Little, David G ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

Anabolism; Bisphosphonate; Bone morphogenetic protein (BMP); Bone tissue engineering; Catabolism

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BMP7 PROTEIN, HUMAN; BONE DENSITY CONSERVATION AGENT; DRUG CARRIER; LACTIC ACID; OSTEOGENIC PROTEIN 1; PAMIDRONIC ACID; POLYLACTIC ACID; POLYMER; RECOMBINANT PROTEIN;

ANIMAL; ARTICLE; BONE; BONE DEVELOPMENT; C57BL MOUSE; DRUG EFFECT; FEMALE; HUMAN; MOUSE; PHYSIOLOGY; QUADRICEPS FEMORIS MUSCLE; TISSUE ENGINEERING;

ANIMALS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; BONE MORPHOGENETIC PROTEIN 7; DIPHOSPHONATES; DRUG CARRIERS; FEMALE; HUMANS; LACTIC ACID; MICE; MICE, INBRED C57BL; OSTEOGENESIS; POLYMERS; QUADRICEPS MUSCLE; RECOMBINANT PROTEINS; TISSUE ENGINEERING;

EID: 79953064873     PISSN: 14732262     EISSN: None     Source Type: Journal    
DOI: 10.22203/eCM.v020a35     Document Type: Article

References (60)

1. Agholme F., Aspenberg P (2009) Experimental results of combining bisphosphonates with allograft in a rat model. J Bone Joint Surg Br 91: 670-675.
2. Baas J., Elmengaard B, Jensen TB, Jakobsen T, Andersen N. T, Søballe K (2008) The Effect of pretreating morselized allograft bone with RhBMP-2 and/or Pamidronate on the fixation of porous Ti and Ha-coated implants. Biomaterials 29: 2915-2922.
3. Bouxsein M., Blake C, Luppen C, Cooper J, Wozney J, Seeherman H. (2001) Interaction between systemic bisphosphonate therapy and bone formation induced by local delivery of RhBMP-2 in non-human primates. J Bone Miner Res 16: S1, S234.
4. Chen W-J, Jingushi S, Hirata G, Matsumoto Y, Iwamoto Y (2004) Intramuscular bone induction by the simultaneous administration of recombinant human bone morphogenetic protein 2 and bisphosphonate for autobone graft. Tissue Eng 10: 1652-1661.
5. Chen W-J, Jingushi S, Jingushi K, Iwamoto Y (2006) In vivo banking for vascularized autograft bone by intramuscular inoculation of recombinant human bone morphogenetic protein-2 and m-tricalcium phosphate. J OrthopSci 11: 283-288.
6. Choi J-Y, Kim H-J, Lee Y-C, Cho B-O, Seong H-S, Cho M., Kim S-G (2007) Inhibition of bone healing by pamidronate in calvarial bony defects. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 103: 321-328.
7. Cooley B. C, Daley RA, Toth JM (2005) Long-term BMP-2-induced bone formation in rat island and free flaps. Microsurgery 25: 167-173.
8. Coxon F. P, Helfrich MH, Van't Hof R, Sebti S, Ralston SH, Hamilton A, Rogers MJ (2000) Protein geranylgeranylation is required for osteoclast formation, function, and survival: inhibition by bisphosphonates and GGTI-298. J Bone Miner Res 15: 1467-1476.
9. DeLustro F, Dasch J, Keefe J, Ellingsworth L (1990) Immune responses to allogeneic and xenogeneic implants of collagen and collagen derivatives. Clin Orthop Relat Res 260: 263-279.
10. Dimitriou R., Giannoudis PV (2005) Discovery and development of BMPs. Injury 36: S28-S33.
11. Friedlaender G. E, Perry CR, Cole J, Cook S, Cierny G, Muschler G. F, Zych GA, Calhoun JH, LaForte AJ, Yin S (2001) Osteogenic protein-1 (Bone Morphogenetic Protein-7) in the treatment of tibial nonunions J Bone Joint Surg Am 83-A Suppl 1: S151-S158.
12. Friess W. (1998) Collagen-biomaterial for drug delivery. Eur J Pharm Biopharm 45: 113-136.
13. Geesink R. GT, Hoefnagels NHM, Bulstra SK (1999) Osteogenic activity of Op-1 Bone morphogenetic protein (BMP-7) in a human fibular defect. J Bone Joint Surg Br 81-B: 710-718.
14. Giannoudis P. V, Einhorn TA, Marsh D (2007) Fracture healing: The diamond concept. Injury 38: S3.
15. Govender S., Csimma C, Genant HK, Valentin-Opran A, Amit Y, Arbel R, Aro H, Atar D, Bishay M, Borner M, Chiron P., Choong P, Cinats J, Courtenay B, Feibel R, Geulette B., Gravel C, Haas N, Raschke M, Hammacher E, van der Velde D, Hardy P, Holt M, Josten C, Ketterl R, Lindeque B., Lob G, MathevonH, McCoy G, Marsh D, Miller R., Munting E, Oevre S, Nordsletten L, Patel A, Pohl A., Rennie W, Reynders P, Rommens P, Rondia J, Rossouw W., Daneel P, Ruff S, Ruter A, Santavirta S, Schildhauer T., Gekle C, Schnettler R, Segal D, Seiler H, Snowdowne R., Stapert J, Taglang G, Verdonk R, Vogels L, Weckbach A, Wentzensen A, Wisniewski T (2002) Recombinant human Bone morphogenetic protein-2 for treatment of open tibial fractures: A prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A: 2123-2134.
16. Green J. R (2005) Zoledronic acid: Pharmacologic profile of a potent bisphosphonate. J Organomet Chem 690: 2439-2448.
17. Greiner S., Kadow-Romacker A, Lübberstedt M, Schmidmaier G., Wildemann B (2007a) The effect of zoledronic acid incorporated in a poly(D, L-lactide) implant coating on osteoblasts in vitro. J Biomed Mater Res A 80A: 769-775.
18. Greiner S., Kadow-Romacker A, Wildemann B, Schwabe P., Schmidmaier G (2007b) Bisphosphonates incorporated in a poly(D, L-lactide) implant coating inhibit osteoclast like cells in vitro. J Biomed Mater Res A 83A: 1184-1191.
19. Greiner S. H, Wildemann B, Back DA, Alidoust M, Schwabe P., Haas NP, Schmidmaier G (2008) Local application of zoledronic acid incorporated in a poly(D, Llactide)-coated implant accelerates fracture healing in rats. Acta Orthop79: 717-725.
20. Harding A. K, Aspenberg P, Kataoka M, Bylski D, Tägil M (2008) Manipulating the anabolic and catabolic response in bone graft remodeling: synergism by a combination of local Bmp-7 and a single systemic dosis of zoledronate. J Orthop Res 26: 1245-1249.
21. Inoda H., Yamamoto G, Hattori T (2007) Rh-BMP2-induced ectopic bone for grafting critical size defects: A preliminary histological evaluation in rat calvariae. Int J Oral Maxillofac Surg 36: 39-44.
22. Itoh K., Udagawa N, Katagiri T, Iemura S, Ueno N, Yasuda H., Higashio K, Quinn JMW, Gillespie MT, Martin TJ, Suda T, Takahashi N (2001) Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of Nuclear Factor-kB ligand. Endocrinology 142: 3656-3662.
23. Jakobsen T., Baas J, Bechtold J, Elmengaard B, Søballe K (2010) The effect of soaking allograft in bisphosphonate: A pilot dose-response sudy. Clin Orthopaed Rel Res 468: 867-874.
24. Jakobsen T., Baas J, Bechtold JE, Elmengaard B, Søballe K. (2007) Soaking morselized allograft in bisphosphonate can impair implant fixation. Clin Orthopaed Rel Res 463: 195-201.
25. Jeppsson C., Åstrand J, Tägil M, Aspenberg P (2003) A combination of bisphosphonate and BMP additives in impacted bone allografts Acta Orthopaed Scand 74: 483-489.
26. Kaneko H., Arakawa T, Mano H, Kaneda T, Ogasawara A, Nakagawa M, Toyama Y, Yabe Y, Kumegawa M, Hakeda Y. (2000) Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 27: 479.
27. Katagiri T., Takahashi N (2002) Regulatory mechanisms of osteoblast and osteoclast differentiation. Oral Dis 8: 147-159.
28. Kato M., Namikawa T, Terai H, Hoshino M, Miyamoto S, Takaoka K (2006a) Ectopic bone formation in mice associated with a lactic acid/dioxanone/ethylene glycol copolymer-tricalcium phosphate composite with added recombinant human bone morphogenetic protein-2. Biomaterials 27: 3927-3933.
29. Kato M., Toyoda H, Namikawa T, Hoshino M, Terai H, Miyamoto S., Takaoka K (2006b) Optimized use of a biodegradable polymer as a carrier material for the local delivery of recombinant human bone morphogenetic protein-2 (RhBMP-2). Biomaterials 27: 2035.
30. Little D., McDonald M, Bransford R, Godfrey C, Amanat N. (2005) Manipulation of the anabolic and catabolic responses with Op-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res 20: 2044-2052.
31. Little D. G, Ramachandran M, Schindeler A (2007) The anabolic and catabolic responses in bone repair. J Bone Joint Surg Br 89-B: 425-433.
32. Luckman S. P, Hughes DE, Coxon FP, Russell RGG, Rogers M. J (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent posttranslational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13: 581-589.
33. Marx R. E, Sawatari, Y., Fortin, M. &Broumand, V. (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63: 1567-1575.
34. Mönkkönen J., Similä J, Rogers MJ (1998) Effects of tiludronate and ibandronate on the secretion of proinflammatory cytokines and nitric oxide from macrophages in vitro. Life Sci 62: 95-102.
35. Mulconrey D. S, Bridwell KH, Flynn J, Cronen GA, Rose P. S (2008) Bone morphogenetic protein (RhBMP-2) as a substitute for iliac crest bone graft in multilevel adult spinal deformity surgery: minimum two-year evaluation of fusion. Spine 33: 2153-2159.
36. Okamoto M., Murai J, Yoshikawa H, Tsumaki N (2006) Bone morphogenetic proteins in bone stimulate osteoclasts and osteoblasts during bone development. J Bone Miner Res 21: 1022-1033.
37. Olsen D., Yang C, Bodo M, Chang R, Leigh S, Baez J, Carmichael D., Perälä M, Hämäläinen E-R, Jarvinen M, Polarek J. (2003) Recombinant collagen and gelatin for drug delivery. Adv Drug Deliv Rev 55: 1547-1567.
38. Rogers M. (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9: 2643-2658.
39. Ruhé P. Q, Wolke JGC, Spauwen PHM, Jansen JA (2006) Calcium phosphate ceramics for bone tissue engineering. In: Tissue Engineering and Artificial Organs (Bronzino JD, ed), Taylor & Francis Group, Boca Raton, FL, pp 38-1-18.
40. Saito N., Murakami N, Takahashi J, Horiuchi H, Ota H, Kato H, Okada T, Nozaki K, Takaoka K (2005) Synthetic biodegradable polymers as drug delivery systems for bone morphogenetic proteins. Adv Drug Deliv Rev 57: 1037-1048.
41. Saito N., Okada T, Horiuchi H, Murakami N, Takahashi J, Nawata M, Ota H, Miyamoto S, Nozaki K, Takaoka K (2001a) Biodegradable poly-D, L-lactic acid-polyethylene glycol block copolymers as a BMP delivery system for inducing bone. J Bone Joint Surg Am 83-A Suppl 1: S92-S98.
42. Saito N., Okada T, Horiuchi H, Murakami N, Takahashi J, Nawata M, Ota H, Nozaki K, Takaoka K (2001b) A biodegradable polymer as a cytokine delivery system for inducing bone formation. Nat Biotech 19: 332.
43. Saito N., Okada T, Horiuchi H, Ota H, Takahashi J, Murakami N., Nawata M, Kojima S, Nozaki K, Takaoka K (2003) Local bone formation by injection of recombinant human bone morphogenetic protein-2 contained in polymer carriers. Bone 32: 381-386.
44. Saito N., Okada T, Toba S, Miyamoto S, Tanaka K (1999) New synthetic absorbable polymers as BMP carriers: plastic properties of poly-D, L-lactic acidpolyethylene glycol block copolymers. J Biomed Mater Res 47: 104-110.
45. Saito N., Takaoka K (2003) New synthetic biodegradable polymers as BMP carriers for bone tissue engineering. Biomaterials 24: 2287-2293.
46. Schindeler A., Morse A, Peacock L, Mikulec K, Yu N, Liu R., Kijumnuayporn S, McDonald M, Baldock P, Ruys A, Little D (2010) Rapid cell culture and pre-clinical screening of a transforming growth factor-beta (TGF-beta) inhibitor for orthopaedics. BMC Musculoskel Dis 11: 105.
47. Schindeler A., Ramachandran M, Godfrey C, Morse A, McDonald M, Mikulec K, Little DG (2008) Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice J Orthop Res 26: 65-74.
48. Schmidmaier G., Wildemann B, Ostapowicz D, Kandziora F., Stange R, Haas NP, Raschke M (2004) Longterm effects of local growth factor (IGF-I and TGF-b1) treatment on fracture healing. A safety study for using growth factors. J Orthop Res 222: 514-519.
49. Schmidmaier G., Wildemann B, Stemberger A, Haas NP, Raschke M (2001) Biodegradable poly(D, L-lactide) coating of implants for continuous release of growth factors. J Biomed Mat Res 58: 449-455.
50. Seeherman H., Blake C, Luppen C, Bouxsein M, Li J, Wozney J. (2000) RhBMP-2 stimulates remodeling and bone formation in a nonhuman primate core defect model. Proc 46th Ann Meet Orthopaed Res Soc, Orlando, FL 25: 1042.
51. Seeherman H., Kiker-Head C, Li X, Bouxsein M, Wozney J. (1998) RhBMP-2 stimulates bone formation in a femoral head core decompression model in adult sheep. Proc 44th Ann Meet Orthopaed Res Soc, New Orleans, LA, pp 65.
52. Seeherman H., Li J, Blake C, Gavin D, Wozney J, Bouxsein M. (2001) Histology indicates bisphosphonate limits transient resorption without decreasing bone induction in nonhuman primate core defects treated with RhBMP-2/ACS. J Bone Miner Res 16: S1, S438.
53. Seeherman H., Li XJ, Bouxsein ML, Wozney JM (2010) RhBMP-2 induces transient bone resorption followed by bone formation in a nonhuman primate core-defect model. J Bone Joint Surg Am 92: 411-426.
54. Tägil M., Aspenberg P, Åstrand J (2006) Systemic zoledronate precoating of a bone graft reduces bone resorption during remodeling. Acta Orthop77: 23-26.
55. Termaat M. F, Den Boer FC, Bakker FC, Patka P, Haarman H. JTM (2005) Bone morphogenetic proteins: Development and clinical efficacy in the treatment of fractures and bone defects. J Bone Joint Surg Am 87: 1367-1378.
56. Thiébaud D., Sauty A, Burckhardt P, Leuenberger P, Sitzler L., Green JR, Kandra A, Zieschang J, Ibarra de Palacios P. (1997) An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tissue Int 61: 386-392.
57. Vaccaro A. R, Patel T, Fischgrund J, Anderson DG, Truumees E., Herkowitz H, Phillips F, Hilibrand A, Albert T (2003) A pilot safety and efficacy study of Op-1 putty (RhBMP-7) as an adjunct to iliac crest autograft in posterolateral lumbar fusions. Eur Spine J 12: 495-500.
58. Yang S. F, Du, ZH, Leong KF, Chua CK (2001) The design of scaffolds for use in tissue engineering. Part I. Traditional factors. Tissue Eng 7: 679-689.
59. Yu N. YC, Schindeler A, Little DG, Ruys AJ (2010) Biodegradable poly(A-hydroxy acid) polymer scaffolds for bone tissue engineering. J Biomed Mater Res B Appl Biomater 93B: 285-295.
60. Zegzula H. D, Buck DC, Brekke J, Wozney JM, Hollinger J. O (1997) Bone formation with use of RhBMP-2 (Recombinant Human Bone Morphogenetic Protein-2). J Bone Joint Surg Am 79: 1778-1790.